Rodman David Malcom, Chief Medical Officer at Mineralys Therapeutics (MLYS), has demonstrated a consistent pattern of selling activity in recent months, with no open-market purchases reported since at least early 2026. SEC Form 4 filings reveal 13 sales transactions between February and March 2026, totaling approximately $1.26 million in aggregate value, with individual sales ranging from $10,696 to $277,922. The transactions were executed alongside smaller derivative transactions marked as "M" (likely option exercises or other equity swaps), including a $68,556 transaction on March 12 and a $59,379 trade on March 13.
Malcom's selling activity has been concentrated in MLYS stock, with no trades disclosed in other companies. The sales occurred in clusters, particularly around mid-February and mid-March 2026, with notable transactions including a $277,922 sale on March 13 and a $173,748 sale the prior day. The pattern suggests a methodical reduction in holdings, as opposed to sporadic disposals. Historically, Malcom has executed $3.55 million in buys against $12.6 million in sells across 55 reported transactions, indicating a long-term net divestment trend. The absence of recent purchases, coupled with the frequency of sales, points to a sustained disposition strategy rather than portfolio rebalancing. All transactions were filed within regulatory deadlines, with no late disclosures noted.
AI-assisted summary